abstract |
The present invention relates to novel proteins interacting with the cytoplasmic domain of CD40, which are useful in the treatment of CD40 and/or NF-KκB related diseases. Surprisingly, these proteins do not show significant homology with the TRAF-protein family and, therefore, offer the possibility to modulate the CD40 and/or NF-κB pathway independently from the TRAF-CD40 interaction. |